刘久江, 林华. 急性呼吸窘迫综合征血清生物标记物的研究进展[J]. 实用临床医药杂志, 2021, 25(23): 124-128. DOI: 10.7619/jcmp.20213576
引用本文: 刘久江, 林华. 急性呼吸窘迫综合征血清生物标记物的研究进展[J]. 实用临床医药杂志, 2021, 25(23): 124-128. DOI: 10.7619/jcmp.20213576
LIU Jiujiang, LIN Hua. Research progress of serum biomarkers in acute respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 124-128. DOI: 10.7619/jcmp.20213576
Citation: LIU Jiujiang, LIN Hua. Research progress of serum biomarkers in acute respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 124-128. DOI: 10.7619/jcmp.20213576

急性呼吸窘迫综合征血清生物标记物的研究进展

Research progress of serum biomarkers in acute respiratory distress syndrome

  • 摘要: 急性呼吸窘迫综合征(ARDS)是由肺内外原因引起的以顽固性低氧血症为显著特征的临床综合征,病死率较高,其诊断主要依靠临床表现,缺乏特异性检验方法,易被忽视。生物标志物的应用可以为ARDS的病理生理机制研究提供重要依据,并且有助于诊断、风险分层和确定候选治疗靶标。本文对近年来ARDS生物标记物的临床应用进展进行综述,并探讨未来的研究方向及前景,以期为精准医学在ARDS管理中的应用提供理论支持。

     

    Abstract: Acute respiratory distress syndrome (ARDS),with high mortality,is a clinical syndrome characterized by intractable hypoxemia induced by internal and external causes.However,the diagnosis mainly depends on clinical diagnosis and lacks specific test,which is often ignored.The use of biomarkers can provide important insights into the pathophysiological mechanism of ARDS and contribute to diagnosis,risk stratification and identification of candidate treatment targets.This study summarized the research progress of biomarkers in the clinical application of ARDS in recent years,and discussed its future research direction and prospects,in order to provide theoretical support for precision medicine in ARDS management.

     

/

返回文章
返回